MNKD - MannKind Corporation
| Previous Close | 1.79 |
| Open | 1.79 |
| Bid | 1.67 x 1000 |
| Ask | 1.70 x 400 |
| Day's Range | 1.67 - 1.80 |
| 52 Week Range | 0.67 - 6.96 |
| Volume | 3,658,841 |
| Avg. Volume | 3,981,553 |
| Market Cap | 249.99M |
| Beta | 3.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.13 |
| Earnings Date | Mar 13, 2017 - Mar 17, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Zacks•9 days ago
MannKind (MNKD) Enters Oversold Territory
MannKind Corporation (MNKD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
- GlobeNewswire•13 days ago
MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering
WESTLAKE VILLAGE, Calif., April 09, 2018-- MannKind Corporation today announced the completion of its previously announced registered direct offering of 14,000,000 shares of common stock and warrants to ...
- Motley Fool•13 days ago
Why MannKind Corporation Stock Sank Last Month
MannKind may be on its last leg.
- Zacks•13 days ago
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
- Motley Fool•16 days ago
Here's Why MannKind Corporation Stock Is Tanking Today
MannKind taps investors for some much-needed capital.
- MarketWatch•16 days ago
MannKind's stock sinks after direct stock offering
Shares of MannKind Corp. sank 15% in premarket trade Friday, after the maker of inhaled therapeutic products announced a direct offering of 14 million shares, and warrants to buy an additional 14 million ...
- GlobeNewswire•16 days ago
MannKind Announces $28.0 Million Registered Direct Offering
WESTLAKE VILLAGE, Calif., April 06, 2018-- MannKind Corporation today announced the pricing of a registered direct offering of 14,000,000 shares of common stock and warrants to purchase up to an aggregate ...
- GlobeNewswire•last month
MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference
WESTLAKE VILLAGE, Calif., March 19, 2018-- MannKind Corporation focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary ...
- Zacks•last month
Options Traders Expect Huge Moves in MannKind (MNKD) Stock
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•last month
MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 14, 2018-- MannKind Corporation focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary ...
- GlobeNewswire•last month
MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., March 13, 2018-- MannKind Corporation focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary ...
- GlobeNewswire•last month
MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million
WESTLAKE VILLAGE, Calif., March 12, 2018--. MannKind Corporation today announced the restructuring of certain of its outstanding debt obligations, reducing outstanding principal by an aggregate of $14.5 ...
- GlobeNewswire•last month
Research Report Identifies Neogen, AgroFresh Solutions, Ocean Rig UDW, Superior Energy Services, root9B Holdings, and MannKind with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Motley Fool•last month
Could MannKind Corporation Be a Millionaire-Maker Stock?
MannKind's stock isn't a compelling contrarian buy.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of MNKD earnings conference call or presentation 27-Feb-18 10:00pm GMT
Q4 2017 MannKind Corp Earnings Call
- Forbes•2 months ago
How Four Managers Outperformed In A Volatile Down Month
February's wild ride has ended with the S&P 500 recovering most of a 10.10% correction to close down 2.82%. Here are four managers who did well in the most volatile, down month we've seen in a long time.
- GlobeNewswire•2 months ago
MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension
WESTLAKE VILLAGE, Calif., March 01, 2018-- MannKind Corporation, focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary ...
- Motley Fool•2 months ago
3 Bright Spots in MannKind Corporation's Q4 Update
It wasn't all bad news in MannKind's latest quarterly earnings announcement.
- Associated Press•2 months ago
MannKind reports 4Q loss
On a per-share basis, the Westlake Village, California-based company said it had a loss of 28 cents. The biopharmaceutical company posted revenue of $4.5 million in the period. For the year, the company ...
- GlobeNewswire•2 months ago
MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results
Q4 and 2 H 2017 Afrezza net revenue were $4.5 million and $6.4 million vs. 2016, respectively Q4 and 2 H 2017 net cash used in operating activities were $30.0 million and $53.3 million, respectively Cash ...
- GlobeNewswire•2 months ago
MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018
WESTLAKE VILLAGE, Calif., Feb. 23, 2018-- MannKind Corporation will release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 and its management will host a conference ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Dare Bioscience and MannKind
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / U.S. markets rallied on Monday, after posting its worst weekly decline in two years, as President Trump unveiled details from his long awaited $200 billion ...
- SmarterAnalyst•2 months ago
MannKind Corporation Appoints Dr. David Kendall as Chief Medical Officer
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of David M. Kendall, MD, as Chief Medical Officer, effective February 12. Dr. Kendall will assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity.
- GlobeNewswire•2 months ago
David Kendall Joins MannKind as Chief Medical Officer
WESTLAKE VILLAGE, Calif., Feb. 06, 2018-- MannKind Corporation today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind’ ...
